Publicaciones en las que colabora con María Esteve Pardo (39)

2024

  1. Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes

    Journal of Crohn's and Colitis, Vol. 18, Núm. 3, pp. 349-359

  2. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612

  3. Safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease

    Digestive and Liver Disease, Vol. 56, Núm. 3, pp. 468-476

  4. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology

2023

  1. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

    Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 3, pp. 771-788.e10

2022

  1. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  2. Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU

    Journal of Clinical Medicine, Vol. 11, Núm. 13

  3. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

  4. Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 16, Núm. 6, pp. 946-953

2021

  1. Clinical features, therapeutic requirements and evolution of patients with Crohn’s disease and upper gastrointestinal involvement (CROHNEX study)

    Alimentary Pharmacology and Therapeutics, Vol. 54, Núm. 8, pp. 1041-1051

  2. Effectiveness and safety of methotrexate monotherapy in patients with Crohn’s disease refractory to anti-TNF-α: results from the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 53, Núm. 9, pp. 1021-1029

  3. Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry

    Digestive Diseases and Sciences, Vol. 66, Núm. 6, pp. 2014-2023

2020

  1. COVID-19 and inflammatory bowel disease: questions arising from patient care and follow-up during the initial phase of the pandemic (February-April 2020)

    Gastroenterologia y Hepatologia, Vol. 43, Núm. 7, pp. 408-413

  2. Correction to: Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry (Surgical Endoscopy, (2020), 34, 3, (1112-1122), 10.1007/s00464-019-06858-z)

    Surgical Endoscopy

  3. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry

    Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616

  4. Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry

    Surgical Endoscopy, Vol. 34, Núm. 3, pp. 1112-1122

2019

  1. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12

  2. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU

    Alimentary Pharmacology and Therapeutics, Vol. 49, Núm. 4, pp. 419-428

  3. EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain

    Therapeutic Advances in Gastroenterology, Vol. 12

2018

  1. Addition of granulocyte/monocyte apheresis to oral prednisone for steroid-dependent ulcerative colitis: A Randomized multicentre clinical trial

    Journal of Crohn's and Colitis, Vol. 12, Núm. 6, pp. 687-694